Two active late stage NS clinical trials are being conducted under an open FDA IND application in the U.S. & QNRX is expanding the study internationally, with a site in Saudi Arabia & plans to open 2 in the U.K. QNRX is also assessing QRX003 in an NS pediatric patient, with 3 pediatric patients in Spain expected to be added shortly, while also expanding QRX003 optionality, studying it in a pediatric patient with PSS. QNRX expects these steps could extend patient populations eligible to participate in QRX003 clinical studies in NS & contribute to the growing database to support its potential regulatory approval and subsequent commercialization.
